TY - JOUR
T1 - Catathrenia under sodium oxybate in narcolepsy with cataplexy
AU - Poli, Francesca
AU - Ricotta, Lara
AU - Vandi, Stefano
AU - Franceschini, Christian
AU - Pizza, Fabio
AU - Palaia, Vincenzo
AU - Moghadam, Keivan Kaveh
AU - Banal, Donatella
AU - Vetrugno, Roberto
AU - Thorpy, Michael J.
AU - Plazzi, Giuseppe
PY - 2012/6
Y1 - 2012/6
N2 - Purpose: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. Methods: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. Results: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. Conclusions: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
AB - Purpose: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. Methods: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. Results: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. Conclusions: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
KW - Groaning
KW - Parasomnia
KW - Side effect
KW - Sleep apnea
KW - Sleep-related breathing disorders
UR - http://www.scopus.com/inward/record.url?scp=84860553541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860553541&partnerID=8YFLogxK
U2 - 10.1007/s11325-011-0520-2
DO - 10.1007/s11325-011-0520-2
M3 - Article
C2 - 21484510
AN - SCOPUS:84860553541
VL - 16
SP - 427
EP - 434
JO - Sleep and Breathing
JF - Sleep and Breathing
SN - 1520-9512
IS - 2
ER -